Spero Therapeutics, Inc. (SPRO) News
Filter SPRO News Items
SPRO News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
SPRO News Highlights
- For SPRO, its 30 day story count is now at 5.
- Over the past 6 days, the trend for SPRO's stories per day has been choppy and unclear. It has oscillated between 1 and 4.
- AIM, DRUG and LUNG are the most mentioned tickers in articles about SPRO.
Latest SPRO News From Around the Web
Below are the latest news stories about Spero Therapeutics Inc that investors may wish to consider to help them evaluate SPRO as an investment opportunity.
Spero Therapeutics (SPRO) Gets a Buy Rating from Berenberg BankIn a report released today, Esther Hong from Berenberg Bank maintained a Buy rating on Spero Therapeutics (SPRO – Research Report), with a price target of $44.00. The company's shares closed last Wednesday at $9.35. According to TipRanks.com, Hong is ranked 0 out of 5 stars with an average return of -23.0% and a 20.8% success rate. Hong covers the Healthcare sector, focusing on stocks such as ACADIA Pharmaceuticals, Aldeyra Therapeutics, and Aprea Therapeutics. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Spero Therapeutics with a $44.00 average price target, representing a 331.8% upside. |
Spero Therapeutics antibiotic SPR206 shows promise in phase 1 trialSpero Therapeutics (SPRO) reported positive results from a phase 1 trial of its antibiotic SPR206 to treat serious multi-drug resistant ((MDR)) gram-negative infections in the… |
Spero Therapeutics Sees Positive Topline Results for Antibiotic TrialBy Chris Wack Spero Therapeutics Inc. said it saw positive topline findings from its Phase 1 bronchoalveolar lavage clinical trial of SPR206, an… |
Spero Therapeutics Announces Positive Topline Results from Phase 1 Bronchoalveolar Lavage Clinical Trial of SPR206, A Novel Intravenous Next Generation Polymyxin Antibiotic for the Treatment of Multi-drug Resistant Gram-Negative Infections in the Hospital SettingSPR206 shown to be well-tolerated; achieved lung exposures consistent with predicted therapeutic levels, when administered three times daily at 100 mg Results support further development of SPR206 in the setting of hospital-acquired pneumonia and ventilator-associated pneumonia CAMBRIDGE, Mass., Feb. 16, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), today announced topline findings from its Phase 1 bronchoalveolar lavage (BAL) clinical trial of SPR206, an intravenously (IV)-a |
The past year for Spero Therapeutics (NASDAQ:SPRO) investors has not been profitableIt's easy to match the overall market return by buying an index fund. Active investors aim to buy stocks that vastly... |
The Petri Dish: Thermo Fisher taps Olaris, bluebird drugs delayedWhile some in the life sciences industry create drugs and devices to tackle the Covid-19 pandemic, their colleagues are busy as ever raising money, testing new drugs, expanding facilities and more. |
Spero granted up to $12.9M by BARDA to develop urinary tract infection drug for childrenSpero Therapeutics < |
Spero Therapeutics Awarded up to an Additional $12.9 Million by BARDA to Support the Development of Orally Administered Tebipenem Pivoxil in Pediatric PatientsNew award option exercised by BARDA brings the total potential funding from its existing contract with Spero up to $59.7 millionCAMBRIDGE, Mass., Jan. 19, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) today announced that the Company and the Biomedical Advanced Research and Development Authority (BARDA), part of the office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services, are expanding their existing partnership to de |
FDA Lifts Clinical Hold On Spero Therapeutics' Lung Infection ProgramThe FDA has lifted the clinical hold on Spero Therapeutics Inc's (NASDAQ: SPRO) Phase 2 trial of SPR720 for nontuberculous mycobacterial (NTM) disease. The SPR720 program was placed on a clinical hold by the FDA following a review of data from a non-human primate (NHP) toxicology study in which mortalities with inconclusive causality to treatment were observed. The FDA's decision to lift the hold follows Spero's submission of a comprehensive study report with detailed analyses from the NHP toxic |
Spero (SPRO) Application for UTI Drug Gets Priority ReviewSpero's (SPRO) NDA for tebipenem HBr oral tablets for complicated urinary tract infections gets Priority Review. |